Protalix BioTherapeutics (PLX) Assets (2010 - 2026)
Protalix BioTherapeutics' quarterly Assets came in at $102.3 million in Q1 2026, up 38.49% year-on-year from $73.9 million in Q1 2025, and up 24.28% quarter-over-quarter from $82.3 million in Q4 2025.
Protalix BioTherapeutics has reported Assets for 17 years, with the latest figure at $102.3 million in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 38.49% year-over-year to $102.3 million; the trailing twelve-month figure through Mar 2026 stood at $102.3 million (up 38.49% YoY), and the FY2025 full-year result was $82.3 million, up 12.16% from the prior year.
- Assets for Q1 2026 stood at $102.3 million, up from $82.3 million in the prior quarter.
- The five-year high for Assets was $102.3 million in Q1 2026, with the low at $55.8 million in Q4 2022.
- Average Assets over 5 years is $76.7 million, with a median of $78.5 million recorded in 2025.
- Year-over-year, Assets sank 43.96% in 2022 and surged 54.42% in 2023.
- Tracing PLX's Assets over 5 years: stood at $55.8 million in 2022, then jumped by 51.35% to $84.4 million in 2023, then retreated by 13.05% to $73.4 million in 2024, then rose by 12.16% to $82.3 million in 2025, then increased by 24.28% to $102.3 million in 2026.
- The last three Assets figures came in at $102.3 million (Q1 2026), $82.3 million (Q4 2025), and $82.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 102.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.34 Mn |
| Dec 31, 2025 | 82.35 Mn |
| Sep 30, 2025 | 82.26 Mn |
| Jun 30, 2025 | 78.49 Mn |
| Mar 31, 2025 | 73.89 Mn |
| Dec 31, 2024 | 73.42 Mn |
| Sep 30, 2024 | 61.56 Mn |
| Jun 30, 2024 | 91.54 Mn |
| Mar 31, 2024 | 89.83 Mn |
| Dec 31, 2023 | 84.43 Mn |
| Sep 30, 2023 | 87.57 Mn |
| Jun 30, 2023 | 88.42 Mn |
| Mar 31, 2023 | 66.56 Mn |
| Dec 31, 2022 | 55.79 Mn |
| Sep 30, 2022 | 56.71 Mn |
| Jun 30, 2022 | 60.64 Mn |
| Mar 31, 2022 | 68.39 Mn |
| Dec 31, 2021 | 73.67 Mn |
| Sep 30, 2021 | 83.48 Mn |
| Jun 30, 2021 | 108.20 Mn |
| Mar 31, 2021 | 102.79 Mn |
| Dec 31, 2020 | 67.93 Mn |
| Sep 30, 2020 | 72.31 Mn |
| Jun 30, 2020 | 71.71 Mn |
| Mar 31, 2020 | 82.88 Mn |
| Dec 31, 2019 | 45.39 Mn |
| Sep 30, 2019 | 53.73 Mn |
| Jun 30, 2019 | 55.24 Mn |
| Mar 31, 2019 | 61.04 Mn |
| Dec 31, 2018 | 61.13 Mn |
| Sep 30, 2018 | 65.75 Mn |
| Jun 30, 2018 | 51.72 Mn |
| Mar 31, 2018 | 64.80 Mn |
| Dec 31, 2017 | 72.21 Mn |
| Sep 30, 2017 | 61.06 Mn |
| Jun 30, 2017 | 59.00 Mn |
| Mar 31, 2017 | 71.85 Mn |
| Dec 31, 2016 | 82.25 Mn |
| Sep 30, 2016 | 70.47 Mn |
| Jun 30, 2016 | 78.86 Mn |
| Mar 31, 2016 | 87.31 Mn |
| Dec 31, 2015 | 97.25 Mn |
| Dec 31, 2014 | 78.36 Mn |
| Mar 31, 2014 | 103.42 Mn |
| Dec 31, 2013 | 113.33 Mn |
| Sep 30, 2013 | 121.16 Mn |
| Jun 30, 2013 | 62.31 Mn |
| Mar 31, 2013 | 69.94 Mn |
| Dec 31, 2012 | 78.73 Mn |
| Sep 30, 2012 | 77.38 Mn |
| Jun 30, 2012 | 84.30 Mn |
| Mar 31, 2012 | 68.46 Mn |
| Dec 31, 2011 | 51.81 Mn |
| Sep 30, 2011 | 60.83 Mn |
| Jun 30, 2011 | 71.89 Mn |
| Dec 31, 2010 | 64.73 Mn |